Skip to main content
GPCR logo

GPCR · Structure Therapeutics Inc.

Track GPCR — free
$41.23 +0.85 (+2.11%) At close · Sep 9
Market Cap
$3.17B
Shares
71.31M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$40.38 Open$46.84 Day$40.26–47.38 52W close$20.20–93.79 Avg vol 30d739K Short int6.1M · 8.5% float · 10.4d Short vol65% Last earningsNov 13, 2024 DataFeb 2023–Sep 2026 Filing10-Q · Aug 6

Up next

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
Trailing 12 months
Net income (TTM)
−$214.84M
Trailing 12 months
Revenue growth YoY
Year over year
Operating margin
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$1.34B
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+26.2%
Year over year · more shares
Price change (1Y)
+93.6%
Trailing year
Short interest
8.5%
Latest settlement · 10.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.7 · calm Equity put/call 0.48
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −26%
below
Price vs 50-day avg −20%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 27%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −25%
trailing
6-month return −28%
trailing
YTD return −42%
this year
Relative strength −42%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $51 › 200d $54 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.53% of float · ▲ +0.5% MoM · 10.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
194 holders — near 3-yr high, broad support
Squeeze score 55
elevated · 0–100
Fundamentals
Poor
EPS growth −3%
Y/Y
Free cash flow $-225.8M
Quant / Vol
risk profile
Very High
Volatility 119%
annualized · 1-yr
Max drawdown −62%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−26% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
27% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $51 › 200d $54 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.53% of float · ▲ +0.5% MoM · 10.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
194 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $20 Now $40 · 27% Range high $94
vs 200-day avg -26% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GPCR
Structure Therapeutics Inc.
this stock
$3.17B -41.9% 8.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
$138.42B +16.7% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$83.15B +5.0% +20.8% 20.0 2.3%
ARGX
Argenx SE
$62.63B +19.8% 1.9%
CSLLY
Csl Ltd
$60.54B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
194
% held
95.5%
Net QoQ
+487.6K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Rising
Shares short
6.1M
Days to cover
10.4d
Change
+30.0K sh
View
Short Volume
Short vol %
65%
As of
Sep 9, 2026
Short Total
View
Fails to Deliver
FTD shares
495
Value
$22.8K
As of
Jul 17, 2026
View
Off-Exchange
Off-exchange %
50.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Thomas R Carper
Amount
$1.0K–$15.0K
Traded
Oct 4, 2023
View
Financials
Financials
Net income (FY)
$-141.2M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 8, 2026
This year
14
View
Proposed Sales
Value
$1.7M
Shares
35.5K
Filed
Jun 25, 2026
View
Exempt Offerings
Offering
$7.0M
Filed
Jan 10, 2022
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 10, 2026
Last call
Jun 9, 2026
View
Investor Relations
Latest news
Structure Therapeutics Reports Po…
Published
Sep 8, 2026
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
GPCR -12.1% -25.0% -28.1% -12.1% -41.9%
SPY -0.1% -0.9% +14.2% -0.1% +12.3%
vs SPY -11.9% -24.0% -42.3% -11.9% -54.3%
Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 135 filings 135 filers Visit website Investor relations